Sinaptica has developed a non-invasive closed-loop precision personalized network modulation of a novel brain target, the Default Mode Network by combining TMS, EEG, and Neuronavigation with a sophisticated machine-learning derived personalization engine. Sinaptica’s patented precision medicine tech represents a totally new electrophysiology-based approach to treating AD and has been granted FDA Breakthrough Status based on unprecedented, published Phase 2 results.
